10x Genomics earnings release, August 6, 2026

10x Genomics, Inc. (TXG) · Form 8-K, Item 2.02 · Filed · SEC filing

10x Genomics Reports Second Quarter 2026 Financial Results

PLEASANTON, Calif.

August 6, 2026 – 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the second quarter ended June 30, 2026.

Recent Updates

• Revenue was $151.0 million for the second quarter of 2026. Excluding $1.6 million related to a patent litigation settlement, revenue was $149.4 million. Revenue increased 3% over the corresponding period of 2025 when excluding non-recurring settlement revenue in both the current and prior-year periods.

• Acquired Proteintech Genomics, a division within Proteintech Group, strengthening the company's multiomics strategy by adding advanced protein detection capabilities to its single cell and spatial platforms.

• Announced multi-year research collaborations with Cleveland Clinic and Lausanne University Hospital to advance research in diagnostic applications of single cell and spatial technologies for cancer care, furthering the company’s diagnostics strategy.

“The story of the quarter was the extraordinary customer response to Atera. We are highly encouraged by the engagement across the research ecosystem and the very strong early order flow,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “Combined with the continued momentum across the rest of the business and our strong operating foundation, we are uniquely well-positioned for the opportunities ahead.”

Second Quarter 2026 Financial Results

Revenue was $151.0 million for the second quarter of 2026, as compared to $172.9 million for the corresponding period of 2025. Excluding $1.6 million and $27.3 million of non-recurring revenue related to patent litigation settlements in the second quarter of 2026 and 2025, respectively, revenue increased 3% over the corresponding period of 2025.

Gross margin was 74% for the second quarter of 2026, as compared to 72% for the corresponding prior year period. The increase in gross margin was primarily due to lower manufacturing costs, which included $2.6 million of tariff refunds, as well as lower inventory write-downs, partially offset by a decrease in non-recurring license and royalty revenue.

Operating expenses were $132.1 million for the second quarter of 2026, a 39% increase from $95.0 million for the corresponding prior year period. The increase was primarily due to a lower gain on settlement of $3.4 million recognized in the second quarter of 2026, as compared to a $40.7 million gain on settlement recognized in the second quarter of 2025. Excluding impacts from settlements, operating expenses were approximately flat year-over-year.

Operating loss was $19.6 million for the second quarter of 2026, as compared to operating income of $30.1 million for the corresponding prior year period.

Net loss was $17.9 million for the second quarter of 2026, as compared to net income of $34.5 million for the corresponding prior year period.

Cash and cash equivalents and marketable securities were $552.0 million as of June 30, 2026.

2026 Financial Guidance

10x Genomics is raising its full year 2026 revenue guidance and now expects revenue in the range of $610 million to $630 million, versus the previous range of $600 million to $625 million. Excluding the non-recurring license and royalty revenue related to patent litigation settlements in both 2026 and 2025, this represents 2% to 5% growth over full year 2025.

Webcast and Conference Call Information

10x Genomics will host a conference call to discuss the second quarter 2026 financial results, business developments and outlook after market close on Thursday, August 6, 2026 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the¹ conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.

About 10x Genomics

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit

10xgenomics.com or connect with us on

LinkedIn,

X,

Facebook,

Bluesky or

YouTube.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended June 30, — (In thousands, except share and per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Products and services revenue149,094145,157298,990282,980
License and royalty revenue1,94227,7512,88944,811
Revenue (1)151,036172,908301,879327,791
Cost of products and services revenue (2)38,53947,82483,20497,262
Gross profit112,497125,084218,675230,529
Operating expenses:Research and development (2)56,79161,224113,638125,469
Operating expenses:Selling, general and administrative (2)78,66174,434145,038164,162
Operating expenses:Gain on settlement-3,400-40,700-3,400-49,900
Operating expenses:Total operating expenses132,05294,958255,276239,731
Operating expenses:Income (loss) from operations-19,55530,126-36,601-9,202
Other income (expense):Interest income4,7974,2719,8117,957
Other income (expense):Interest expense-3-3
Other income (expense):Other income (expense), net-3,8872,603-4,7024,739
Other income (expense):Total other income9106,8715,10912,693
Other income (expense):Income (loss) before provision for income taxes-18,64536,997-31,4923,491
Other income (expense):Provision for (benefit from) income taxes-7142,459-913,311
Other income (expense):Net income (loss)-17,93134,538-31,401180
Other income (expense):Net income (loss) per share, basic-0.140.28-0.240
Other income (expense):Net income (loss) per share, diluted-0.140.28-0.240
Other income (expense):Weighted-average shares used to compute net income (loss) per share, basic129,984,169123,755,409129,050,312123,183,924
Other income (expense):Weighted-average shares used to compute net income (loss) per share, diluted129,984,169124,509,720129,050,312124,258,150

Income Statement

Three Months Ended June 30, — The following table represents total revenue by source for the periods indicated (in thousands). Spatial includes the Company’s Visium and Xenium products:

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
InstrumentsSingle Cell3,0875,7278,31011,640
InstrumentsSpatial4,5748,77010,61317,672
InstrumentsTotal instruments revenue7,66114,49718,92329,312
ConsumablesSingle Cell88,45185,788177,345169,897
ConsumablesSpatial42,30136,39783,20867,644
ConsumablesTotal consumables revenue130,752122,185260,553237,541
ConsumablesServices10,6818,47519,51416,127
ConsumablesProducts and services revenue149,094145,157298,990282,980
ConsumablesLicense and royalty revenue1,94227,7512,88944,811
ConsumablesTotal revenue151,036172,908301,879327,791

Income Statement

Three Months Ended June 30, — The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
AmericasUnited States*82,109103,491158,802190,309
AmericasAmericas (excluding United States)2,9172,6676,3236,419
AmericasTotal Americas85,026106,158165,125196,728
AmericasEurope, Middle East and Africa39,97234,73476,82466,629
Asia-PacificChina14,96823,17030,80540,053
Asia-PacificAsia-Pacific (excluding China)11,0708,84629,12524,381
Asia-PacificTotal Asia-Pacific26,03832,01659,93064,434
Asia-PacificTotal revenue151,036172,908301,879327,791

Income Statement

Three Months Ended June 30, — Includes stock-based compensation expense as follows: (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Cost of revenue1,8361,9893,7544,470
Research and development10,53312,61321,22826,719
Selling, general and administrative13,24712,64323,27627,132
Total stock-based compensation expense25,61627,24548,25858,321

Balance Sheet

(In thousands) (in thousands)

June 30, 2026December 31, 2025
Current assets:Cash and cash equivalents502,512473,966
Current assets:Marketable securities49,52149,443
Current assets:Accounts receivable, net47,54547,013
Current assets:Other receivables3,08435,480
Current assets:Inventory52,61656,341
Current assets:Prepaid expenses and other current assets19,39322,208
Current assets:Total current assets674,671684,451
Current assets:Property and equipment, net215,324226,711
Current assets:Operating lease right-of-use assets56,68560,450
Current assets:Goodwill6,9184,511
Current assets:Intangible assets, net61,16062,329
Current assets:Other noncurrent assets15,3082,913
Current assets:Total assets1,030,0661,041,365
Current liabilities:Accounts payable20,69412,733
Current liabilities:Accrued compensation and related benefits24,74442,500
Current liabilities:Accrued expenses and other current liabilities30,37739,971
Current liabilities:Deferred revenue23,61023,902
Current liabilities:Operating lease liabilities12,01510,985
Current liabilities:Contingent consideration, current7,06923,363
Current liabilities:Total current liabilities118,509153,454
Current liabilities:Contingent consideration, noncurrent2,9911,237
Full release

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," “outlook,” "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s products, services, business strategy, collaborations and opportunities and 10x Genomics, Inc.’s financial performance and results of operations, including expectations regarding revenue and guidance. These statements are based on management's current expectations, forecasts, beliefs, estimates, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics’ expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2025 filed on February 12, 2026 and the company’s quarterly report on Form 10-Q for the quarter ended June 30, 2026 to be filed with the U.S. Securities and Exchange Commission (“SEC”), and elsewhere in the documents 10x Genomics, Inc. files with the SEC from time to time.

Disclosure Information

10x Genomics uses filings with the Securities and Exchange Commission, its website ( www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

Investors: investors@10xgenomics.com

Media: media@10xgenomics.com²

10x Genomics, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

__________________________³

(1)

The following table represents total revenue by source for the periods indicated (in thousands). Spatial includes the Company’s Visium and Xenium products:

(1)

The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):

*

Includes license and royalty revenue.

(2)

Includes stock-based compensation expense as follows:⁴

10x Genomics, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands)⁵

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.